TICKERNOMICS Sign up
Last Update: 2024-03-28 02:16:01
Petros Pharmaceuticals Inc. ( PTPI ) https://www.petrospharma.com
1.54USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
PTPI
5.84%
SPY
32.74%
-95.78%
PTPI
SPY
92.93%
PTPI
0.00%
SPY
224.41%
PTPI
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
3.26
-4.73
0.68
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.01
0.47
0.46
-267.22
0.00
0.47
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-287.02
75.61
-128.20
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
1105.77
-68.44
0.00
Other Earnings and Cash Flow Stats:
Petros Pharmaceuticals Inc. ( PTPI ) Net Income TTM ($MM) is -242.00
Petros Pharmaceuticals Inc. ( PTPI ) Operating Income TTM ($MM) is -23.89
Petros Pharmaceuticals Inc. ( PTPI ) Owners' Earnings Annual ($MM) is 0.00
Petros Pharmaceuticals Inc. ( PTPI ) Current Price to Owners' Earnings ratio is 0.00
Petros Pharmaceuticals Inc. ( PTPI ) EBITDA TTM ($MM) is -18.20
Petros Pharmaceuticals Inc. ( PTPI ) EBITDA Margin is -128.20%
Capital Allocation:
Petros Pharmaceuticals Inc. ( PTPI ) has paid 0.00 dividends per share and bought back -0.04941 million shares in the past 12 months
Petros Pharmaceuticals Inc. ( PTPI ) has reduced its debt by 0.853675 million USD in the last 12 months
Capital Structure:
Petros Pharmaceuticals Inc. ( PTPI ) Interest-bearing Debt ($MM) as of last quarter is 9
Petros Pharmaceuticals Inc. ( PTPI ) Annual Working Capital Investments ($MM) are -2
Petros Pharmaceuticals Inc. ( PTPI ) Book Value ($MM) as of last quarter is 7
Petros Pharmaceuticals Inc. ( PTPI ) Debt/Capital as of last quarter is 143%
Other Balance Sheet Stats:
Petros Pharmaceuticals Inc. ( PTPI ) has 17 million in cash on hand as of last quarter
Petros Pharmaceuticals Inc. ( PTPI ) has 8 million of liabilities due within 12 months, and long term debt 8 as of last quarter
Petros Pharmaceuticals Inc. ( PTPI ) has 2 common shares outstanding as of last quarter
Petros Pharmaceuticals Inc. ( PTPI ) has 0 million USD of preferred stock value
Academic Scores:
Petros Pharmaceuticals Inc. ( PTPI ) Altman Z-Score is -3.94 as of last quarter
Petros Pharmaceuticals Inc. ( PTPI ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Petros Pharmaceuticals Inc. ( PTPI ) largest shareholder is owning shares at 0.00 ($MM) value
WALKER WAYNE REMELL(an insider) Bought 22642 shares of Petros Pharmaceuticals Inc. ( PTPI ) for the amount of $0.00 on 2021-12-22
32.66% of Petros Pharmaceuticals Inc. ( PTPI ) is held by insiders, and 1.95% is held by institutions
Petros Pharmaceuticals Inc. ( PTPI ) went public on 2020-12-02
Other Petros Pharmaceuticals Inc. ( PTPI ) financial metrics:
FCF:-7.77
Unlevered Free Cash Flow:25.16
EPS:-8.59
Operating Margin:-287.02
Gross Profit Margin:75.61
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-262.50
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Petros Pharmaceuticals Inc. ( PTPI ) :
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Preion Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor preion medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.